Harrow Re-Launches VERKAZIA for Pediatric Eye Disease, Targeting Underserved Market
Event summary
- Harrow re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for vernal keratoconjunctivitis (VKC) on June 10, 2026.
- VERKAZIA is the second of three priority products in Harrow's portfolio, following a comprehensive commercial strategy focused on physician education and patient access.
- VKC is a chronic, potentially sight-threatening condition affecting children, with limited treatment options before VERKAZIA's approval.
- Clinical trials showed VERKAZIA significantly improved corneal damage and reduced the need for corticosteroid rescue therapy.
The big picture
Harrow's re-launch of VERKAZIA addresses a significant unmet need in pediatric ophthalmology, particularly for a condition that has historically lacked FDA-approved steroid-sparing therapies. The move aligns with broader industry trends toward targeted immunomodulatory treatments for chronic inflammatory diseases. With VKC's chronic nature and pediatric onset, sustained demand for safe, well-tolerated therapies like VERKAZIA is likely to drive long-term market potential.
What we're watching
- Market Penetration
- Whether Harrow can successfully educate physicians and remove access barriers to drive adoption of VERKAZIA in the underserved VKC market.
- Competitive Dynamics
- How existing treatments and potential new entrants may impact VERKAZIA's market share in the long-term management of VKC.
- Regulatory Compliance
- The pace at which Harrow can address ongoing communications with the FDA regarding compliance and quality plans at its outsourcing facility.